文献速递结核与非结核分枝杆菌细菌感染、耐药与抗菌药物

非洲与非非洲国家参与者中性粒细胞计数的差异:两项国际临床试验分析

Differences in Neutrophil Counts Between African and Non-African Countries in 2 International Clinical Trials.
PubMed 文献 · J Infect Dis · 2025-01-01

两项国际结核治疗试验中,337名参与者接受10 mg/kg利福平,另三组分别接受10、15、20 mg/kg利福喷丁每日治疗2个月。黑人非洲参与者基线中性粒细胞计数中位数低于黑人非非洲参与者(P = .004),非洲入组是中性粒细胞减少的独立相关因素,所有中性粒细胞减少事件均自行缓解且未中断治疗。

要点

  • 黑人非洲参与者基线ANC中位数低于黑人非非洲参与者(P = .004)。
  • CTCAE定义的3级及以上中性粒细胞减少共32例(其中28例在非洲),不同利福喷丁剂量间比例无差异。
  • DAIDS标准仅会报告4例事件,所有中性粒细胞减少事件均自行缓解且未中断治疗。

核心结论

  • 基线ANC中位数差异可能导致不良事件误分类或不当临床管理。
  • 非洲国家入组是发生中性粒细胞减少的独立相关因素。
  • 制定和使用人群特异性ANC正常值可改进研究和临床管理指导。

研究设计与样本

  • 两项国际结核治疗试验中,337名参与者接受10 mg/kg利福平每日治疗2个月。
  • 三组参与者分别361、81、81名接受10、15、20 mg/kg利福喷丁每日治疗2个月。
  • 基线及治疗第2、4、6、8、12周测量ANC,分析中性粒细胞减少相关因素。

主要发现

  • 黑人非洲参与者基线ANC中位数低于黑人非非洲参与者(P = .004)。
  • CTCAE定义的3级及以上中性粒细胞减少发生于32名参与者,其中28名在非洲。
  • 不同利福喷丁剂量间中性粒细胞减少比例无差异。
  • DAIDS标准仅会报告4例事件。
  • 所有中性粒细胞减少事件均自行缓解且未中断治疗。

关键数值与推荐

  • CTCAE 2.0-4.0版定义3级中性粒细胞减少为ANC 500-999 cells/μL。
  • DAIDS 2.0版定义3级中性粒细胞减少为ANC 400-599 cells/μL。

临床怎么用

  • 原文未涉及临床实践推荐。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Differences in absolute neutrophil count (ANC) between African and non-African populations have been reported. Neutropenia has also been reported during rifamycin use. ANC values in current tables that assign severity grades to clinical or laboratory events (National Cancer Institute Common Terminology Criteria for Adverse Events [CTCAE] and the National Institute of Allergy and Infectious Diseases Division of AIDS [DAIDS]) might not consistently be applicable among different populations. METHODS: During 2 international tuberculosis treatment trials, 337 participants received 10 mg/kg of rifampin, and 3 groups of 361, 81, and 81 participants received 10, 15, and 20 mg/kg of rifapentine, respectively, for 2 months of daily treatment. ANC was measured at baseline and after 2, 4, 6, 8, and 12 weeks of treatment. CTCAE versions 2.0-4.0 and DAIDS version 2.0 define neutropenia grade 3 as ANC 500-999 cells/μL and ANC 400-599 cells/μL, respectively. We analyzed factors associated with neutropenia. RESULTS: Baseline median ANC was lower in Black African participants than in Black non-African participants (P = .004). CTCAE-defined grade 3 or higher neutropenia occurred in 32 (28 in Africa) participants. Proportions did not differ between rifapentine doses. Only 4 events would have been reported by DAIDS criteria. All neutropenia events resolved spontaneously without interrupting treatment. Enrollment in an African country was an independent factor associated with the development of neutropenia. CONCLUSIONS: Differences in baseline median ANC can result in misclassification of adverse events or inappropriate clinical management. Development and use of population-specific normal values of ANC could improve guidance for research and clinical management.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Moro RN, Johnson JL, Martinson N, et al. Differences in Neutrophil Counts Between African and Non-African Countries in 2 International Clinical Trials. J Infect Dis. 2025. PMID: 40447276. doi:10.1093/infdis/jiaf291

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。